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According to the 2008 World Health Organization classification, chronic neutrophilic leukemia, chronic myelomonocytic
leukemia and atypical chronic myeloid leukemia are rare diseases. The remarkable progress in our understanding of the
molecular genetics of myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms has made it
clear that there are some specific genetic abnormalities in these 3 rare diseases. At the same time, there is considerable
overlap among these disorders at the molecular level. The various combinations of genetic abnormalities indicate a
multi-step pathogenesis, which likely contributes to the marked clinical heterogeneity of these disorders. This review
focuses on the current knowledge and challenges related to the molecular pathogenesis of chronic neutrophilic
leukemia, chronic myelomonocytic leukemia and atypical chronic myeloid leukemia and relationships between
molecular findings, clinical features and prognosis.
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Chronic neutrophilic leukemia (CNL), chronic myelo-
monocytic leukemia (CMML) and atypical chronic
myeloid leukemia (CML) are rare diseases categorized
into the 2008 World Health Organization (WHO) as
either myeloproliferative neoplasms (MPN; CNL) or
myelodysplastic/myeloproliferative neoplasms (MDS/
MPN; CMML and a CML). These diseases share several
characteristics including an enlarged liver and spleen, an
increased WBC and a hyper-cellular bone marrow. They
are distinguished from each other based on numbers and
types of leukemia cells in the blood, appearance of
leukemia cells in the blood and bone marrow cells and
cytogenetic and molecular abnormalities including ab-
sence of t(9:22) and BCR/ABL1 and rearrangement of
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unless otherwise stated.(PDGFRA), platelet-derived growth factor receptor, beta
polypeptide (PDGFRB) or fibroblast growth factor recep-
tor 1 (FGFR1). Previously, it was sometimes difficult to
distinguish these disease from each other and from other
MPNs including chronic myeloid leukemia (CML), poly-
cythaemia vera (PV), essential thrombocythaemia (ET)
and primary myelofibrosis (PMF) which have different
molecular abnormalities including mutations in Janus
kinase 2 (JAK2), calreticulin (CALR) and MPL proto-
oncogene, thrombopoietin receptor (MPL). Molecular
characterization of CNL, CMML and atypical CML has
advanced even further with the use of next generation se-
quencing. Important genetic abnormalities have been
identified which help to distinguish between these dis-
eases. This review focuses on the current knowledge and
challenges related to the molecular pathogenesis of CNL,
CMML and atypical CML and relationships between mo-
lecular findings, clinical features and prognosis.Molecular genetics of CNL
Colony stimulating factor 3 receptor (CSF3R) mutations
In 2013, Maxson et al. reported frequent mutations in
CSF3R in patients with CNL and atypical CML [1]. SuchThis is an Open Access article distributed under the terms of the Creative
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mutations were found. CSF3RT618I and CSF3RT615A are
most common mutations, which are in the membrane
proximal region which mediates proliferative and sur-
vival signals. These mutations occur alone or with an-
other nonsense mutations truncating the cytoplasmic
tail of the coding region important in transduction of
maturation and suppression of proliferation [1,2]. Mem-
brane proximal mutations result in activation of JAK
signaling pathways and truncation mutations in prefer-
ential activation of SRC family–TNK2 kinase signaling
(Figure 1A) [1]. The aetiological role of CSF3RT618I muta-
tion in these diseases was studied in a model in which mice
transplanted with CSF3RT618I–expressing hematopoietic
cells. These mice developed a CNL-like phenotype charac-
terized by hyper-cellular bone marrow and granulocyte
infiltrates in the spleen and liver and died [3].
Pardanani et al. [4] sequenced the implicated exons of
CSF3R in 35 suspected subjects with CNL, 12 subjects
with confirmed CNL and 6 subjects with CNL and a
monoclonal gammopathy or lymphoid neoplasm. All
subjects who fulfilled the 2008 WHO criteria for CNL
had a CSF3R proximal membrane mutation, most fre-
quently CSF3RT618I. One subject had CSF3RM696T and 1,
CSF3RI598I. One of these subjects also had a truncating
CSF3R mutation. No one with WHO-defined CNL but
with a monoclonal gammopathy or lymphoid neoplasm
had a CSF3R mutation. These data explain the different
bases and prognoses between CNL with and without a
monoclonal gammopathy [5-8]. Our study in Chinese
with WHO-defined CNL confirmed these findings [9].
We found a CSF3RT618I mutation in all subjects with
CNL without a monoclonal gammopathy but not in 2
subjects with features of CNL with a monoclonal gam-
mopathy. These data indicate CSF3R mutations are a
highly sensitive and specific molecular marker for WHO-
defined CNL and we suggest it be included into the revised
criteria.
JAK2 V617F
JAK2 V617F is common in patients with BCR/ABL1 nega-
tive MPNs and is rare in patients with CML but not
in those with lymphoid neoplasms, reactive myelo-
proliferative disorders or normals [10,11]. About 13 pa-
tients with CNL with JAK2 V617F are reported [12-20].
These patients had typical features of CNL without the
erythrocytosis, thrombocytosis and bone marrow fibrosis
typical of PV, ET and PMF, but CSF3R mutations were
not tested. Other recent studies report no JAK2 V617F in
patients with CNL with CSF3R mutations [4,9]. Also
controversial is whether patients with CNL and JAK2 V617F
have a different prognosis than patients with CNL without
JAK2 V617F. Some data suggest CNL with JAK2V617F muta-
tion has an indolent course with long intervals of stabledisease on hydroxyurea [12]. Other data suggest person
with CNL and JAK2V617F have a worse prognosis and a
high risk of transformation to AML [13,14]. The under-
lying issue, of course, is whether the current WHO-criteria
are sufficient to accurately diagnose CNL. Do patients with
seeming CNL but with JAK2V617F rather than a CSF3R mu-
tation really have CNL or a different disorder not currently
recognized in the WHO-criteria. This distinction is arbi-
trary but we favor reserving the CNL-designation in future
revisions of the WHO-criteria for patients with CSF3R
mutations. This would, of course, require a new designator
for patients with a clinical phenotype resembling CNL but
with JAK2V617F. This situation is distinct than those in
which a person with a CNL phenotype and a CSF3R
mutation can also have a 2nd mutation such as SETBP1
(see below).
SET binding protein 1 (SETBP1) mutations
Three small studies reported SETBP1 mutations in some
patients with CNL [4,9,21]. Pardanani et al. [4] reported
6 of 34 patients with clinically-suspected CNL had
SETBP1 mutations and 4 of 12 patients with WHO-
defined CNL had SETBP1 mutation and CSF3RT618I. We
found SETBP1 mutations in 6 of 8 patients with CNL
with CSF3RT618I [9]. Piazza et al. [21] reported a
SETBP1 mutation in 4 patients with CNL and a CSF3R
mutation. These patients had a worse prognosis than
those with CNL without a SETBP1 mutation [4,21,22],
an observation requires confirmation.
Molecular genetics of CMML
Mutations are detected in about 90 percent of patients
with CMML [23-25]. These mutations are clustered into
four categories: (1) mutations involving epigenetic regu-
lator genes (Figure 1B) [23-26]; (2) mutations involv-
ing the spliceosome component pathway (Figure 1C)
[27-30]; (3) mutations involving transcription factors
[24,31-33]; and (4) mutations involving signaling regulator
genes [24,26,34-37].
Epigenetic regulator gene mutations
Mutations in tet methylcytosine dioxygenase 2 (TET2)
mutations are detected in 40–60 percent of patients
with CMML [24,26,38,39]. There is controversy whether
TET2 mutations in patients with CMML is associated
with prognosis. Kosmider et al. [38] reported TET2 mu-
tation was associated with a poor prognosis but this was
not confirmed in 2 recent large series [24,30]. Muta-
tions in DNA (cytosine-5-)-methylthransferase 3 alpha
(DNMT3A) and isocitrate dehydrogenase 1/2 (IDH1/2) are
rare in CMML [24,26,40]. DNMT3A mutations trended to
occur in CMML-2 and were reported in 6 of 20 patients
with CMML-derived AML [26]. Additional sex combs like
transcriptional regulator 1 (ASXL1) mutations are detected
AB
C
Figure 1 Somatic mutations affect genes involved in CSF3R (A), epigenetic regulation (B) and RNA splicing (C).
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are reported to have a higher WBC and higher levels of
monocytes and immature myeloid cells in the blood
[24,30]. Clinical features of patients with CMML and
c.1934dupG;p.G646WfsX12 are similar to those of patients
with other ASXL1 mutations [24,30]. Conclusions from 2
large series about prognostic impact of ASXL1 mutations
on survival are contradictory. Itzykson et al. reported
ASXL1 mutation was an unfavorable independent prog-
nostic factor [24]. However, data from Patnaik et al.
showed that ASXL1 mutations had no impact on survival
[30]. This controversy requires resolution. Enhancer of
zeste 2 polycomb repressive complex 2 subunit (EZH2)
mutations are uncommon in CMML [24].
Spliceosome component mutations
About 60 percent of patients with CMML have mutations
in genes involved in RNA-splicing [24]. Most common are
mutations in serine/arginine-rich splicing factor 2 (SRSF2)
in 30–50 percent of cases. These mutations are associated
with increased age, less pronounced anemia and a diploid
karyotype but not with prognosis [24,28,29,42]. SRSF2 or
zinc finger (CCCH type), RNA-binding motif and serine/
arginine rich 2 (ZRSR2) mutations are frequently concord-
ant with TET2 mutations [24,28,43].
Mutations affecting transcription
Mutations in the runt-related transcription factor 1
(RUNX1) transcription factor are detected in 15–40 per-
cent of patients with CMML [24,31-33]. Patients with
CMML and RUNX1 mutations may have a higher risk of
transformation to AML [31,33]. CCAAT/enhancer bindingFigure 2 A schematic approach, outlining the evaluation for a patien
genetics test should include mutations involved JAK2, CALR, MPL, CSF3R, T
arrangement of PDGFRA, PDGFRB or FGFR1. AML, Acute myeloid leukaemia
leukemia; CMML, chronic myelomonocytic leukemia; MDS, myelodysplastic
myelodysplastic/myeloproliferative neoplasms.protein, alpha (CEBPA) mutations are rare in patients with
CMML [33].
Signaling regulator gene mutations
Kosmider et al. [35] reported variant CSF3R somatic
mutations in about 4 percent of patients with CMML
with high concordance for ASXL1 mutations. These pa-
tients were reported to have a poor prognosis. SETBP1
mutations are detected in about 5 percent of patients
with CMML and are associated with a poor prognosis in
patients who also have an ASXL1 mutation [35-37].
SETBP1 and CSF3R mutations seem mutually exclusive
in CMML. Cbl proto-oncogene, E3 ubiquitin protein lig-
ase (CBL) mutations are detected in about 10 percent of
patients with CMML [24,34,44,45].
Recently, Itzykson et al. tracked mutations in single-cell-
derived myeloid colonies after in vitro culture in patients
with CMML [25]. Their data indicate a preferential order
of mutation acquisition in progenitor cells. Mutations in
TET2 (or IDH1 and IDH2) or ASXL1 occur 1st followed
by mutations in SRSF2 or spliceosome component path-
way genes followed by mutations in signal transduction-
related genes [25]. These data recall data from studies of
the relationship between temporal acquisition of mutations
of JAK2V617F and TET2 or ASXL1 in patients with other
MPNs where clinical and laboratory features are correlated
with which mutation occurs 1st [46,47].
Molecular genetics of atypical CML
SETBP1 mutations
SETBP1 mutations are detected in about 25–30 percent
of patients with atypical CML [21,48]. These patientst presenting with peripheral blood leukocytosis. * Molecular
ET2, SRSF2, ZRSR2, ASXL1, SETBP1 and BCR-ABL1 fusion genes and re-
; CML, chronic myelogenous leukemia; CNL,Chronic neutrophilic
syndromes; MPN, myeloproliferative neoplasms; MDS/MPN,
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without SETBP1 mutations [21]. SETBP1 mutations are
associated with del(7) and iso(17)(q10)), ASXL1 and CBL
mutations are exclusive of JAK2 and TET2 mutations in
patients with atypical CML [48]. Recent study [49] showed
that overexpression of SETBP1 associated with micro-
RNA desregulation in MPN.
Other mutations
CSF3R mutations do not occur in patients with atypical
CML [4]. In contrast, TET2 mutations are common
[23,37,48,50]. ASXL1 mutations [20,51] are detected in
20–70 percent of patients with atypical CML and SRSF2
mutations about 40 percent [51]. SRFS2, SETBP1 and
ASXL1 mutations are often confounded [51].
Next-generation sequencing (NGS) in MPN and MDS/MPN
NGS technology, such as whole-exons sequencing (WES)
has demonstrated its power in re-sequecing human ge-
nomes to enhance our understanding of how molecular
genetics affect MPN and MDS/MPN [1,15,16,21,25]. How-
ever, the challenge is to provide genetic information in a
timely and affordable way. Thus, the utility of detailed tar-
geted resequencing by capturing technologies is currently
reasonable in clinical practicality. Consequently, molecular
biomarkers will soon no longer be sequenced individually.
Instead, panels of biomarkers will be assessed in a mas-
sively parallel way with high sensitivity and multiplexing in
patients with MPN or MDS/MPN for diagnosis and indi-
vidualized treatment regimens.
Conclusion
The mutational landscapes or terrains of CNL, CMML
and atypical CML are complex, but some mutations are
relatively specific in these 3 disorders. Furthermore, the
order in which mutations are acquired may correlate
with clinical features and prognosis. Therefore, analyse of
mutations in MPNs is increasingly important for several
reasons. 1st, mutation analyses is useful in trying to deter-
mine the aetiology of an increased WBC. For example,
mutations in CSF3R suggest CNL, SETBP1 mutations,
atypical CML and concurrent TET2 and SRSF2 or ZRSR2
mutations, CMML. Analyses of these frequently mutated
genes can determine clonality and distinguish neoplasms
from non-neoplastic increases in the WBC (Figure 2). 2nd,
mutations in ASXL1, SEBP1, DNMT3A are associated, al-
beit inconsistently, with a poor prognosis in MPNs and
MDS/MPNs. These data, if confirmed, could be added to
prognostic scoring systems. 3rd, identifying specific mo-
lecular abnormalities can suggest new therapy targets for
these diseases, such as hedgehog pathway inhibitors [52].
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